Here are five notes:
1. VIEKIRA XR is an extended-release co-formulation of the active ingredients in VIEKIRA PAK.
2. It is intended to treat patients with chronic genotype 1 hepatitis C virus infection, including those with compensated cirrhosis.
3. The FDA approved VIEKIRA XR based on data from seven Phase III clinical trials that included more than 2,300 patients.
4. VIEKIRA XR is taken orally with meals.
5. AbbVie is a global, research-based biopharmaceutical company founded in 2013.
More articles on GI/endoscopy:
5 most read GI/endoscopy stories: July 18 — 22
Schizophrenic son of gastroenterologist Dr. William Wu found guilty of stabbing him: 5 notes
LifeBond’s surgical sealant kit receives FDA IDE approval: 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.